Resources

In order to help you expedite the request process with us, we put together a quick prescription guideline.

5 common questions about the supplement that may be useful for ALS, Parkinson's and Alzheimers.

New analysis of Biogen’s aducanumab shows reduction in clinical decline in Alzheimer’s disease.

As a pioneer of a completely new type of global service, we understand that trust, security and credibility are paramount–especially when paying for medicines which are essential and often the only treatment option available. There are an increasing number of scam websites and we ourselves have been the subject of one such scam. In this article we’ll give you tips on how to spot these fakers.

I’m lucky. It's been 4 years since the first MND symptoms, only my voice has been impacted.

Two and a half years after his diagnosis, David found a medicine with off-label application for MND.

Kyowa Hakko Kirin's Parkinson's therapy, Nourianz (istradefylline), gains FDA approval as an add-on to levodopa/carbidopa.

Radicut/Radicava (edaravone), shown to slow the progression of ALS, is now approved for patients in China.

Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.

Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.

After 40 years with primary biliary cholangitis, Fiona's mother is still alive thanks to her daughter's dedication and a liver transplant.

After 3 years of living with ALS, Marc found a new medicine on the other side of the world. 

With tears, laughter and hope, Mark and his family find their own way to cope with ALS.

Diagnosed with ALS only 6 months ago, Peter went against the current to find more options to treat his disease.

MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses.